Artwork
iconShare
 
Manage episode 507858429 series 3301410
Content provided by Literal Humans. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Literal Humans or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

This week on Tech Can’t Save Us, host Paul David is joined by Dr. Joel Braunstein, co-founder, CEO, and president of C2N Diagnostics, a pioneering biotech company transforming the way we diagnose Alzheimer’s disease.
They explore how C2N is advancing blood-based diagnostic tools, most notably the Precivity AD test that delivers accuracy comparable to PET scans and spinal taps, but in a simpler, less invasive format. Joel shares how these innovations are reducing misdiagnosis rates, empowering clinicians, and providing families with clarity during some of their most difficult moments.
Joel reflects on his journey from cardiologist at Johns Hopkins to biotech founder, the curiosity and persistence that drive his work, and the importance of balancing rapid innovation with clinical rigor. He also shares personal insights, quickfire takes on tech innovation, and the philosophies that keep him grounded.
Find more about C2N Diagnostics here: https://www.c2n.com
Follow Dr.Braustein: https://www.linkedin.com/in/joel-braunstein-md-9456611/
  continue reading

171 episodes